文献速递主动脉疾病血液透析通路

单把ProGlide血管闭合装置在EVAR中的安全性与有效性

Safety and effectiveness of single ProGlide vascular access in patients undergoing endovascular aneurysm repair.
PubMed 文献 · J Vasc Surg · 2020-04-08

该回顾性队列研究纳入131例择期经皮腹主动脉瘤腔内修复术(EVAR)患者,评估每侧血管入路单把ProGlide闭合的安全性与有效性。116例双侧单把ProGlide闭合,15例至少一侧非单把闭合。结果显示单把ProGlide使用与VARC-2或BARC标准事件无显著差异,无假性动脉瘤或需重复干预的出血,提示对于鞘管直径≤16F的入路,单把ProGlide闭合安全有效。

要点

  • 单把ProGlide用于EVAR入路闭合,鞘管直径≤16F时安全有效。
  • 双侧单把ProGlide闭合组VARC-2事件率6/116(5.17%),非单把组2/15(13.3%)。
  • 单把ProGlide使用与VARC-2或BARC标准事件无显著关联。

核心结论

  • 对于接受EVAR的患者,每侧血管入路使用单把ProGlide闭合是安全有效的方法,适用于鞘管直径≤16F。

研究设计与样本

  • 回顾性队列研究,纳入2015年11月至2017年12月在QEII健康科学中心所有择期经皮EVAR病例,共131例。

主要发现

  • VARC-2标准事件发生在8/131(6.11%)患者中,双侧单把组6/116(5.17%),非单把组2/15(13.3%)。
  • BARC标准事件发生在6/131(4.58%)患者中,双侧单把组5/116(4.31%),非单把组1/15(6.67%)。
  • 单把ProGlide使用与VARC-2(OR 0.35;95%CI 0.64-1.94)或BARC(OR 0.63;95%CI 0.07-6.79)标准事件无显著差异。
  • 无患者发生假性动脉瘤或需要重复干预的出血。

关键数值与推荐

  • VARC-2标准事件:双侧单把组6/116(5.17%),非单把组2/15(13.3%)。
  • BARC标准事件:双侧单把组5/116(4.31%),非单把组1/15(6.67%)。
  • 单把ProGlide使用与VARC-2的OR为0.35(95%CI 0.64-1.94),与BARC的OR为0.63(95%CI 0.07-6.79)。
  • 右侧股动脉鞘管直径中位数16F(IQR 16F-18F),左侧14F(IQR 14F-16F)。

临床怎么用

  • 在EVAR术中,对于鞘管直径≤16F的入路,可考虑每侧使用单把ProGlide进行闭合。
  • 单把ProGlide闭合未增加VARC-2或BARC标准事件风险,且无假性动脉瘤或需重复干预的出血。

局限性

  • 回顾性研究设计,样本量较小(共131例),非单把ProGlide组仅15例。
  • 单中心研究,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The objective of this study was to evaluate the safety and effectiveness of single ProGlide use per bilateral access site for endovascular aneurysm repair (EVAR) of abdominal aortic aneurysms. METHODS: A retrospective cohort study was performed for all elective percutaneous EVARs from November 2015 to December 2017 at the QEII Health Sciences Centre (Halifax, Nova Scotia, Canada). Exposure of interest was number of ProGlides used per access site, dichotomized into bilateral single ProGlide closure vs nonsingle ProGlide closure on at least one femoral arteriotomy. Outcomes included Valve Academic Research Consortium (VARC)-2 and Bleeding Academic Research Consortium (BARC) criteria. Groups were compared with Fisher exact test, analysis of variance, or Wilcoxon rank sum, as appropriate. Logistic regression was used to compare the effect of single ProGlide use on VARC-2 and BARC criteria. RESULTS: A total of 131 cases were included, of which 116 had bilateral single ProGlide use for access closure. Baseline characteristics including comorbidities and smoking status were compared between groups. Groups were similar for all characteristics except smoking status, with an increased proportion of former smokers in the nonsingle ProGlide group. There were 119 (90.8%) patients who had single ProGlide use on the right femoral artery and 121 (92.4%) on the left; 16 (12.2%) patients had ProGlide deployment issues. Median maximal right and left femoral sheath diameters were 16F (interquartile range [IQR], 16F-18F) and 14F (IQR, 14F-16F), respectively. Median length of stay was 1 day (IQR, 1-1 day). VARC-2 criteria occurred in 8 of 131 (6.11%) patients, 6 of 116 (5.17%) with bilateral single ProGlides and 2 of 15 (13.3%) with nonsingle ProGlides. BARC criteria occurred in 6 of 131 (4.58%) patients, 5 of 116 (4.31%) with bilateral single ProGlides and 1 of 15 (6.67%) with nonsingle ProGlides. Single ProGlide use was not associated with a difference in VARC-2 (odds ratio, 0.35; 95% confidence interval, 0.64-1.94) or BARC (odds ratio, 0.63; 95% confidence interval, 0.07-6.79) criteria. No patients developed pseudoaneurysms or required repeated intervention for bleeding. CONCLUSIONS: Single ProGlide use per vascular access site in patients undergoing EVAR is a safe and effective method for access closure with sheath diameters up to and including 16F.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Dunn K, Jessula S, Herman CR, et al. Safety and effectiveness of single ProGlide vascular access in patients undergoing endovascular aneurysm repair. J Vasc Surg. 2020. PMID: 32276013. doi:10.1016/j.jvs.2020.03.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。